Assembly Biosciences计划于2026年第四季度启动Abi-6250治疗HDV的二期临床研究

美股速递05-22 19:01

Assembly Biosciences Inc. 宣布，计划在2026年第四季度启动其候选药物Abi-6250用于治疗丁型肝炎病毒（HDV）感染的二期临床研究。这一举措标志着该公司在开发针对这一严重肝脏疾病的新型疗法方面迈出了关键一步。HDV感染被认为是病毒性肝炎中最严重的一种形式，目前治疗选择极为有限，因此Abi-6250的临床进展备受关注。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1174745774?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-22 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174745774","market":"us","top_or_hot":-1,"title":"Assembly Biosciences计划于2026年第四季度启动Abi-6250治疗HDV的二期临床研究","media":"美股速递","content":"<p>Assembly Biosciences Inc. 宣布，计划在2026年第四季度启动其候选药物Abi-6250用于治疗丁型肝炎病毒（HDV）感染的二期临床研究。这一举措标志着该公司在开发针对这一严重肝脏疾病的新型疗法方面迈出了关键一步。HDV感染被认为是病毒性肝炎中最严重的一种形式，目前治疗选择极为有限，因此Abi-6250的临床进展备受关注。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assembly Biosciences计划于2026年第四季度启动Abi-6250治疗HDV的二期临床研究</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssembly Biosciences计划于2026年第四季度启动Abi-6250治疗HDV的二期临床研究\n</h2>\n\n<h4 class=\"meta\">\n\n2026-05-22 19:01 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Assembly Biosciences Inc. 宣布，计划在2026年第四季度启动其候选药物Abi-6250用于治疗丁型肝炎病毒（HDV）感染的二期临床研究。这一举措标志着该公司在开发针对这一严重肝脏疾病的新型疗法方面迈出了关键一步。HDV感染被认为是病毒性肝炎中最严重的一种形式，目前治疗选择极为有限，因此Abi-6250的临床进展备受关注。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ASMB","symbol_name":"Assembly Biosciences Inc.","start_time":0,"source_url":"","article_id":"1174745774","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174745774","pubTimestamp":1779447683,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Assembly Biosciences Inc. 宣布，计划在2026年第四季度启动其候选药物Abi-6250用于治疗丁型肝炎病毒（HDV）感染的二期临床研究。这一举措标志着该公司在开发针对这一严重肝脏疾病的新型疗法方面迈出了关键一步。HDV感染被认为是病毒性肝炎中最严重的一种形式，目前治疗选择极为有限，因此Abi-6250的临床进展备受关注。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"ASMB":"Assembly Biosciences Inc.","BK4139":"生物科技"},"translate_title":"Assembly Biosciences plans to initiate Phase II clinical study of Abi-6250 for HDV in the fourth quarter of 2026","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASMB":1},"content_text":"Assembly Biosciences Inc. 宣布，计划在2026年第四季度启动其候选药物Abi-6250用于治疗丁型肝炎病毒（HDV）感染的二期临床研究。这一举措标志着该公司在开发针对这一严重肝脏疾病的新型疗法方面迈出了关键一步。HDV感染被认为是病毒性肝炎中最严重的一种形式，目前治疗选择极为有限，因此Abi-6250的临床进展备受关注。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1174745774","isCrawlerRequest":true}